Amylyx Pharmaceuticals, Inc.AMLX
| Dec 31, 2022 |
---|
Cash and cash equivalents | 63 |
---|
Short-term investments | 284 |
---|
Prepaid expenses and other current assets | 10 |
---|
Accounts receivable, net | 15 |
---|
Inventories | 10 |
---|
Total current assets | 382 |
---|
Property and equipment, net | 3 |
---|
Restricted cash equivalents | 1 |
---|
Operating lease right-of-use assets | 6 |
---|
Other assets | 0 |
---|
Total assets | 391 |
---|
Accounts payable | 6 |
---|
Accrued Liabilities and Other Liabilities | 38 |
---|
Operating Lease, Liability, Current | 2 |
---|
Total current liabilities | 47 |
---|
Operating Lease, Liability, Noncurrent | 4 |
---|
Total liabilities | 51 |
---|
Common Stock, Value, Issued | 0 |
---|
Additional paid-in capital | 695 |
---|
Accumulated deficit | -354 |
---|
Accumulated other comprehensive (loss) income | -0 |
---|
Total stockholders' equity (deficit) | 341 |
---|
Total liabilities, redeemable convertible preferred stock and stockholders'equity (deficit) | 391 |
---|